# Diagnostic Value of MRI-targeted Plus Index-lesion-ipsilaterally Systematic Biopsy for Biopsy-naive Men At Risk of Prostate Cancer

> **NCT06584279** · — · RECRUITING · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 563 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Biopsy of the prostate and pathological diagnosis

## Key facts

- **NCT ID:** NCT06584279
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10
- **Primary completion:** 2025-02
- **Final completion:** 2025-04
- **Target enrollment:** 563 (ESTIMATED)
- **Last updated:** 2024-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06584279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06584279, "Diagnostic Value of MRI-targeted Plus Index-lesion-ipsilaterally Systematic Biopsy for Biopsy-naive Men At Risk of Prostate Cancer". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT06584279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*